SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease
- PMID: 30992196
- DOI: 10.1016/S2213-8587(19)30116-0
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease
Comment on
-
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13. Lancet Diabetes Endocrinol. 2019. PMID: 30992195 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
